BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Domain Not Resolving

HSTS

DNSSEC

Organization Schema

IPv6

Apache

Person Schema

Google

Google Cloud

U.S. Server Location

Executive Assistant to Chief Financial Officer and Chief Accounting Officer

Annalisa Nielsen

President and Chief Medical Officer

Barrett Katz

CSO and Site Head, Gene Therapy

Clayton Beard

Chief Business Officer, BridgeBioX

James Li

Chief Operating Officer, Skeletal Dysplasias and Gene Therapy

Justin To

Chief Executive Officer at QED Therapeutics Oncology and Chief Commercial Officer at BridgeBio

Matt Outten

Chief Business Officer

Michael Henderson

CEO and Founder

Neil Kumar

Chief Product Officer

Thomas Trimarchi

Vice President, Clinical Development

Agnieszka 'Aj' J.

Randy Scott

Andrea Ellis

Laura A. Brege

Co-Founder & CEO

Uma Sinha

Chief Scientific Officer

Josh Loehrer

SVP, People

President and Chief Operating Officer

Charles Homcy

Co-Founder

Frank McCormick

Co-founder

Ali Panjwani

Director, Pricing & Contracting, Market Access

Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.

MyoKardia is a clinical-stage biopharmaceutical company that develops targeted therapies for the treatment of rare cardiovascular diseases.

Pharmaceutical Public Companies With More Than $50M in Revenue

Western US Companies With Less Than $1B in Revenue (Top 10K)

Pharmaceutical Companies With More Than 10 Employees (Top 10K)

Health Care Companies (Top 10K)

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

Post-IPO Equity - BridgeBio

Blue Owl

Post-IPO Debt - BridgeBio

Qatar Investment Authority

Post-IPO Secondary - BridgeBio

Kohlberg Kravis Roberts

Viking Global Investors

Series D - BridgeBio

Series C - BridgeBio

Palo Alto

California

United States

North America

BridgeBio

BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Pfizer amyloidosis rival from BridgeBio wins FDA nod (PFE:NYSE)

BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition with Pfizer

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

SHP2 inhibitor targeting MAPK/RAS driven cancers, currently in clinical development.

AAV5 gene therapy for congenital adrenal hyperplasia, undergoing Phase 1/2 clinical trials.

AAV gene therapy for classic galactosemia, in IND-enabling studies.

Recombinant collagen 7 for dystrophic epidermolysis bullosa, with completed Phase 2 trials.

Topical PI3KA inhibitor for venous and lymphatic malformations, in Phase 1/2 trials.

GO inhibitor for primary hyperoxaluria type 1 and recurrent kidney stone formers, with completed Phase 1 trials.

India

Asia

United Kingdom

Europe

Canada

Indonesia

HTML5

Lightbox

HubSpot Marketing Hub

Vimeo

GoDaddy Premium DNS

Google Tag Manager

GoDaddy

HubSpot Forms

Google Fonts

Wordpress

BridgeBio owns QED Therapeutics

BridgeBio owns GondolaBio

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Sep 16, 2024 1:46 PM	de915bee
public peers	general	Sep 16, 2024 9:44 AM	f82287c3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 16, 2024 10:16 AM	88a09b5d
company summary	general
signals	general	Sep 16, 2024 9:44 AM	ea9e49c0
crunchbase trigger	general	Nov 27, 2024 12:50 PM	9e057d21
crunchbase profile	general	Nov 28, 2024 10:13 AM	c5387467
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 11:15 AM	aab01ab1
peers	general	Sep 16, 2024 9:44 AM	598b867e
news basic	general	Sep 16, 2024 9:44 AM	05f93c02
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:BRIDGEBIOPHARMA

BridgeBio Pharma